MPN Congress 2022 | Targeting JAK2 V617F VAF in polycythemia vera & the efficacy of ropeginterferon alfa-2b
Alison Moliterno
• 31 Oct 2022
Alison Moliterno, MD, Johns Hopkins Medicine, Baltimore, MD, explains how JAK2 V617F mutations in hematopoietic stem cells (HSCs) lead to the development of polycythemia vera (PV), highlighting the need to develop therapies that not only reduce blood counts but also reduce the JAK2 mutant allele burden at the stem cell level, mentioning the example of ropeginterferon alfa-2b. This interview took place at the 14th International Congress on Myeloproliferative Neoplasms (MPN Congress) held in New York City, NY.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting with Pharmessentia and Protagonist
